Related Experiment Videos
Research and development commitments in an integrated plasma collection and plasma fractionation environment
1Haemonetics Plasma Product Services, Lille, France.
Seminars in Thrombosis and Hemostasis
|May 14, 1998
Summary
Producing safe plasma derivatives requires advanced testing and purification methods. Continuous research is key to developing innovative and safer plasma products for biopharmaceutical applications.
Area of Science:
- Biopharmaceutical science
- Plasma protein chemistry
Background:
- Plasma fractionation is a complex biopharmaceutical field.
- Ensuring safety of plasma derivatives is paramount.
- Detection of infection markers and viral reduction are critical.
Purpose of the Study:
- To highlight the scientific demands in plasma fractionation.
- To emphasize the need for sensitive detection and purification technologies.
- To underscore the importance of research and development for novel plasma products.
Main Methods:
- Development and application of sensitive testing technologies for infection markers.
- Implementation of nondenaturing plasma protein purification techniques.
- Utilizing efficient viral reduction strategies.
Main Results:
- Safe plasma derivatives rely on rigorous testing and purification.
- Nondenaturing methods preserve protein function.
- Viral reduction technologies enhance product safety.
Conclusions:
- Plasma fractionation demands high scientific rigor.
- Continuous R&D is essential for safer, innovative plasma products.
- Understanding and controlling infection markers and viral load are critical for biopharmaceutical success.